Trial Profile
An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2022
Price :
$35
*
At a glance
- Drugs Simurosertib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 01 Jun 2022 Results from (NCT032619475 and NCT037082116) assessing the effect of TAK-931 on corrected QT (QTc) intervals at clinically relevant doses published in the Clinical Pharmacology in Drug Development
- 25 Sep 2021 Results of a Pop PK analysis characterizing sources of variability on PK of TAK-931 in adult patients with advanced solid tumors ; using data from three clinical studies: NCT02699749, NCT03261947 and NCT03708211 published in the Journal of Clinical Pharmacology
- 01 Oct 2020 Status changed from active, no longer recruiting to completed.